| ²é¿´: 1026 | »Ø¸´: 4 | |||
xbqewpqÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
»êÙâ
|
[ÇóÖú]
·úÂíÎ÷Äá×¢ÉäÒº½ø¿Ú±ê×¼
|
| RT£¬ÇóÖú·úÂíÎ÷Äá×¢ÉäÒº½ø¿Ú±ê×¼£¬ÔÁϺÍ×¢ÉäÒºµÄ¶¼ÏëÒª£¬ÓÐľÓа¡£¿ |
» ²ÂÄãϲ»¶
314Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
08¹¤¿Æ 320×Ü·Ö Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
085601ר˶£¬×Ü·Ö342Çóµ÷¼Á£¬µØÇø²»ÏÞ
ÒѾÓÐ5È˻ظ´
085600²ÄÁÏÓ뻯¹¤µ÷¼Á 324·Ö
ÒѾÓÐ4È˻ظ´
311Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
»¯¹¤Ñ§Ë¶306Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
²ÄÁÏÓ뻯¹¤Ò»Ö¾Ô¸Äϲý´óѧ327Çóµ÷¼ÁÍÆ¼ö
ÒѾÓÐ9È˻ظ´
311Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÈýÀàÐÂÒ©É걨Óë¸ÃÒ©½ø¿ÚÉêÇëÖ®¼äµÄ¹ØÏµ£¿
ÒѾÓÐ11È˻ظ´
ÒÀÍÐßäõ¥Ö¬·¾Èé×¢ÉäÒº
ÒѾÓÐ8È˻ظ´
ÆÏÌÑÌÇ×¢ÉäÒºÎÞ¾ú¼ì²é·½·¨ÇóÖú
ÒѾÓÐ5È˻ظ´
ÇóÖú°¢ÌæÂå¶û×¢ÉäÒºµÄÁÙ´²Ó¦ÓÃ
ÒѾÓÐ3È˻ظ´
ÇóÑÎËá°±äåË÷×¢ÉäÒº½ø¿Ú±ê×¼
ÒѾÓÐ2È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚ×¢ÉäÒºÖлîÐÔÌ¿µÄÓÃÁ¿ÎÊÌâ
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿ÑÎËá¶¡¿©µØ¶ûÂÈ»¯ÄÆ×¢ÉäÒº¸ßЧҺÏà²â¶¨ÎÊÌâ
ÒѾÓÐ9È˻ظ´
¡¾ÇóÖú¡¿Çó×¢ÉäÒºÖÆ¼Á´¦·½¹¤ÒÕ±ä¸üÑо¿10ºÅ¡¢11ºÅ¡¢14ºÅÄ£°å
ÒѾÓÐ4È˻ظ´

yugijiang
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 661 (²©Ê¿)
- ¹ó±ö: 0.005
- ½ð±Ò: 4018.4
- ºì»¨: 11
- Ìû×Ó: 1790
- ÔÚÏß: 178Сʱ
- ³æºÅ: 416091
- ×¢²á: 2007-06-29
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
xbqewpq: ½ð±Ò+5, ¡ïÓаïÖú 2012-08-04 21:41:03
soundhorizo: ½ð±Ò+2, ר¼ÒÐÁ¿à ÖÜÄ©Óä¿ì ^^ 2012-08-05 00:15:13
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
xbqewpq: ½ð±Ò+5, ¡ïÓаïÖú 2012-08-04 21:41:03
soundhorizo: ½ð±Ò+2, ר¼ÒÐÁ¿à ÖÜÄ©Óä¿ì ^^ 2012-08-05 00:15:13
|
British Pharmacopoeia Volume I & II Monographs: Medicinal and Pharmaceutical Substances Flumazenil General Notices (Ph. Eur. monograph 1326) C15H14FN3O3 303.3 78755-81-4 Action and use Benzodiazepine receptor antagonist. Ph Eur DEFINITION Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate. Content 99.0 per cent to 101.0 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Very slightly soluble in water, freely soluble in methylene chloride, sparingly soluble in methanol. mp 198 ¡ãC to 202 ¡ãC. IDENTIFICATION Infrared absorption spectrophotometry (2.2.24). Comparison Ph. Eur. reference spectrum of flumazenil. TESTS Appearance of solution The solution is clear (2.2.1) and is not more intensely coloured than reference solution BY7 (2.2.2, Method II). Dissolve 0.10 g in methanol R and dilute to 10 mL with the same solvent. Impurity C Maximum 1 per cent. Dissolve 0.10 g in 0.5 mL of methylene chloride R and dilute to 10 mL with butanol R. To 5.0 mL of this solution add 2.0 mL of ninhydrin solution R and heat in a water-bath at 95 ¡ãC for 15 min. Any blue-purple colour in the solution is not more intense than that in a standard prepared at the same time and in the same manner using 5.0 mL of a 0.1 g/L solution of dimethylformamide diethylacetal R in butanol R. Related substances Liquid chromatography (2.2.29). Test solution Dissolve 50.0 mg of the substance to be examined in 5 mL of methanol R and dilute to 25.0 mL with the mobile phase. Reference solution (a) Dissolve 2.0 mg of flumazenil impurity B CRS and 2.0 mg of the substance to be examined in the mobile phase and dilute to 25.0 mL with the mobile phase. Dilute 2.0 mL of this solution to 25.0 mL with the mobile phase. Reference solution (b) Dilute 10.0 mL of the test solution to 100.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 100.0 mL with the mobile phase. Column: ¡ª size: l = 0.25 m, Ø = 4.6 mm, ¡ª stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 µm). Mobile phase To 800 mL of water R adjusted to pH 2.0 with phosphoric acid R, add 130 mL of methanol R and 70 mL of tetrahydrofuran R and mix. Flow rate 1 mL/min. Detection Spectrophotometer at 230 nm. Injection 20 µL. Run time 3 times the retention time of flumazenil. Relative retention With reference to flumazenil (retention time = about 14 min): impurity A = about 0.4; impurity D = about 0.5; impurity E = about 0.6; impurity B = about 0.7; impurity F = about 2.4. System suitability Reference solution (a): ¡ª resolution: minimum 3.0 between the peaks due to impurity B and flumazenil. Limits: ¡ª impurity B: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent), ¡ª unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent), ¡ª total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (0.2 per cent), ¡ª disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent). Loss on drying (2.2.32) Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 ¡ãC. Sulfated ash (2.4.14) Maximum 0.1 per cent, determined on 1.0 g in a platinum crucible. ASSAY Dissolve 0.250 g in 50 mL of a mixture of 2 volumes of acetic anhydride R and 3 volumes of anhydrous acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20). 1 mL of 0.1 M perchloric acid is equivalent to 30.33 mg of C15H14FN3O3. IMPURITIES Specified impurities B, C. Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use): A, D, E, F. A. R = H, R¡ä = F: 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, B. R = C2-H5, R¡ä = OH: ethyl 8-hydroxy-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate, E. R = C2H5, R¡ä = H: ethyl 5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate, F. R = C2H5, R¡ä = Cl: ethyl 8-chloro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate, C. diethoxy-N,N-dimethylmethanamine, D. 7-fluoro-4-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione. |
2Â¥2012-08-04 14:15:41
xbqewpq
ÈÙÓþ°æÖ÷ (ÖøÃûдÊÖ)
»êÙâ
- ACI: 10
- Ó¦Öú: 483 (˶ʿ)
- ¹ó±ö: 1.827
- ½ð±Ò: 8677.9
- É¢½ð: 2014
- ºì»¨: 36
- ɳ·¢: 14
- Ìû×Ó: 2144
- ÔÚÏß: 533.9Сʱ
- ³æºÅ: 1820818
- ×¢²á: 2012-05-16
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
- ¹ÜϽ: ·ÖÎö

3Â¥2012-08-04 21:40:47
ll9999
ר¼Ò¹ËÎÊ (ÎÄ̳¾«Ó¢)
-

ר¼Ò¾Ñé: +584 - Ó¦Öú: 8021 (½ÌÊÚ)
- ¹ó±ö: 60.073
- ½ð±Ò: 290576
- É¢½ð: 2941
- ºì»¨: 710
- ɳ·¢: 28
- Ìû×Ó: 37510
- ÔÚÏß: 3178.5Сʱ
- ³æºÅ: 1410396
- ×¢²á: 2011-09-21
- ÐÔ±ð: MM
- רҵ: ÇøÓò·¢Õ¹¹ÜÀí
- ¹ÜϽ: µçÄÔʹÓÃ
4Â¥2012-08-05 00:23:39
³ÕÒÄ×ÓÆ¤
°æÖ÷ (ÎÄ̳¾«Ó¢)
ÀÏÆ¦
- ACI: 12
- Ó¦Öú: 2016 (½²Ê¦)
- ¹ó±ö: 5.368
- ½ð±Ò: 54487.3
- É¢½ð: 41688
- ºì»¨: 303
- ɳ·¢: 1206
- Ìû×Ó: 32611
- ÔÚÏß: 4303.7Сʱ
- ³æºÅ: 674536
- ×¢²á: 2008-12-14
- ÐÔ±ð: GG
- רҵ: ÎÞÉñÂÛ
- ¹ÜϽ: ÈËÎÄÉç¿Æ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
soundhorizo: ½ð±Ò+5, Ó¦ÖúÖ¸Êý+1, Ӧ¥Ö÷ÒªÇó ¸ÐлӦÖú 2012-08-06 09:14:07
soundhorizo: ½ð±Ò+5, Ó¦ÖúÖ¸Êý+1, Ӧ¥Ö÷ÒªÇó ¸ÐлӦÖú 2012-08-06 09:14:07
| ½ø¿Ú×¢²á±ê×¼£¬Ò»°ãÍøÉϺÜÉÙÓÐÃâ·Ñ£¬½¨ÒéÕÒ±ê×¼··×ÓRMB¹ºÂò¡£ÂÛ̳ÉÏÓв»ÉÙ±ê×¼··×Ó¡£ |

5Â¥2012-08-06 08:31:29













»Ø¸´´ËÂ¥